Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis

References

• Bourebaba N, Marycz K. Hepatic stellate cells role in the course of metabolic disorders development - A molecular overview. Pharmacol Res. 2021;170:105739.
   PubMed Web of Science ®Google Scholar
• Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol. 2018;29(1):14–21.
   PubMed Web of Science ®Google Scholar
• Dhar D, Baglieri J, Kisseleva T, et al. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96–108.
   PubMed Web of Science ®Google Scholar
• Devhare PB, Sasaki R, Shrivastava S, et al. Exosome-Mediated intercellular communication between hepatitis C virus-infected hepatocytes and hepatic stellate cells. J Virol. 2017;91(6):e02225–e02216.
   PubMed Web of Science ®Google Scholar
• Khomich O, Ivanov AV, Bartosch B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis. Cells. 2019;9(1):24.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Li YP, Liu QH, et al. Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology. 2021;73(3):1140–1157.
   PubMed Web of Science ®Google Scholar
• Golbabapour S, Bagheri-Lankarani K, Ghavami S, et al. Autoimmune hepatitis and stellate cells: an insight into the role of autophagy. Curr Med Chem. 2020;27(35):6073–6095.
   PubMed Web of Science ®Google Scholar
• Xu T, Pan LX, Li LY, et al. MicroRNA-708 modulates hepatic stellate cells activation and enhances extracellular matrix accumulation via direct targeting TMEM88. J Cell Mol Med. 2020;24(13):7127–7140.
   PubMed Web of Science ®Google Scholar
• Naim A, Baig MS. Matrix metalloproteinase-8 (MMP-8) regulates the activation of hepatic stellate cells (HSCs) through the ERK-mediated pathway. Mol Cell Biochem. 2020;467(1–2):107–116.
   PubMed Web of Science ®Google Scholar
• Liu X, Xu J, Rosenthal S, et al. Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology. 2020;158(6):1728–1744.
   PubMed Web of Science ®Google Scholar
• Mu M, Zuo S, Wu RM, et al. Ferulic acid attenuates liver fibrosis and hepatic stellate cell activation via inhibition of TGF-β/Smad signaling pathway. Drug Des Devel Ther. 2018;12:4107–4115.
   PubMed Web of Science ®Google Scholar
• Stegmann C, Hochdorfer D, Lieber D, et al. A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells. PLoS Pathog. 2017;13(4):e1006273.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6(1):33453.
   PubMed Web of Science ®Google Scholar
• Wei J, Feng LS, Li Z, et al. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother. 2013;67(5):387–392.
   PubMed Web of Science ®Google Scholar
• Lan T, Zhuang LH, Li SW, et al. Polydatin attenuates hepatic stellate cell proliferation and liver fibrosis by suppressing sphingosine kinase 1. Biomed Pharmacother. 2020;130:110586.
   PubMed Web of Science ®Google Scholar
• Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
   PubMed Web of Science ®Google Scholar
• Guo FX, Wu Q, Li P, et al. The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling. Cell Death Differ. 2019;26(9):1670–1687.
   PubMed Web of Science ®Google Scholar
• Yang Z, Jiang S, Shang JJ, et al. LncRNA: shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev. 2019;52:17–31.
   PubMed Web of Science ®Google Scholar
• Chen XM, Ma H, Gao Y, et al. Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2. Bioengineered. 2021 Dec;12(1):6738–6747.
   PubMed Web of Science ®Google Scholar
• Zhang K, Shi ZM, Zhang MX, et al. Silencing lncRNA Lfar1 alleviates the classical activation and pyoptosis of macrophage in hepatic fibrosis. Cell Death Dis. 2020;11(2):132.
   PubMed Web of Science ®Google Scholar
• Shen XT, Guo HY, Xu JJ, et al. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019;234(10):18169–18179.
   PubMed Web of Science ®Google Scholar
• Siddiqui ZH, Abbas ZK, Ansari MW, et al. The role of miRNA in somatic embryogenesis. Genomics. 2019;111(5):1026–1033.
   PubMed Web of Science ®Google Scholar
• Choi SW, Lee JY, Kang KS. miRNAs in stem cell aging and age-related disease. Mech Ageing Dev. 2017;168:20–29.
   PubMed Web of Science ®Google Scholar
• Guo XX, Yang WN, Dong BS, et al. Glycyrrhetinic acid-induced miR-663a alleviates hepatic stellate cell activation by attenuating the TGF- β/Smad signaling pathway. Evid Based Complement Alternat Med. 2020;2020:3156267.
   PubMed Web of Science ®Google Scholar
• Zhou GY, Li CX, Zhan YT, et al. Pinostilbene hydrate suppresses hepatic stellate cell activation via inhibition of miR-17-5p-mediated Wnt/β-catenin pathway. Phytomedicine. 2020;79:153321.
   PubMed Web of Science ®Google Scholar
• Riaz F, Chen Q, Lu KK, et al. Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway. J Cell Mol Med. 2021;25(8):4073–4087.
   PubMed Web of Science ®Google Scholar
• Ge SF, Wu XP, Xiong Y, et al. HMGB1 inhibits HNF1A to modulate liver fibrogenesis via p65/miR-146b signaling. DNA Cell Biol. 2020;39(9):1711–1722.
   PubMed Web of Science ®Google Scholar
• Gong LJ, Wu X, Li XY, et al. S1PR3 deficiency alleviates radiation-induced pulmonary fibrosis through the regulation of epithelial-mesenchymal transition by targeting miR-495-3p. J Cell Physiol. 2020;235(3):2310–2324.
   PubMed Web of Science ®Google Scholar
• Chang N, Ge JJ, Xiu L, et al. HuR mediates motility of human bone marrow-derived mesenchymal stem cells triggered by sphingosine 1-phosphate in liver fibrosis. J Mol Med (Berl). 2017;95(1):69–82.
   PubMed Web of Science ®Google Scholar
• Hou L, Yang L, Chang N, et al. Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome. Front Immunol. 2020;11:1149.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhi F, Lun W, et al. Baicalin inhibits PDGF‑BB‑induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR‑3595/ACSL4 axis. Int J Mol Med. 2018;41:1992‑2002.
   Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Kumar P, Nagarajan A, and Uchil PD. Analysis of Cell Viability by the MTT Assay. Cold Spring Harb Protoc. 2018;20183 :469-471.
   Google Scholar
• Zhang L, Zhang Z, Qin L, et al. SDF2L1 inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma. Biomed Res Int. 2020 Aug 7;2020:1970936.
   PubMed Web of Science ®Google Scholar
• Telford WG. Multiparametric analysis of apoptosis by flow cytometry. Methods Mol Biol. 2018;1678:167–202.
   PubMedGoogle Scholar
• Kim B. Western blot Techniques. Methods Mol Biol. 2017;1606:133–139.
   PubMedGoogle Scholar
• Zhou XQ, Chang YZ, Zhu LR, et al. LINC00839/miR-144-3p/WTAP (WT1 Associated protein) axis is involved in regulating hepatocellular carcinoma progression. Bioengineered. 2021;12(2):10849–10861.
   PubMed Web of Science ®Google Scholar
• Yu SY, Peng H, Zhu Q, et al. Silencing the long noncoding RNA NORAD inhibits gastric cancer cell proliferation and invasion by the RhoA/ROCK1 pathway. Eur Rev Med Pharmacol Sci. 2019;23(9):3760–3770.
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang L, Xu F. LncRNA NORAD stimulates proliferation and migration of renal cancer via activating the miR-144-3p/MYCN axis. Eur Rev Med Pharmacol Sci. 2020;24(20):10426–10432.
   PubMed Web of Science ®Google Scholar
• Tao W, Li YJ, Zhu M, et al. LncRNA NORAD promotes proliferation and inhibits apoptosis of gastric Cancer by regulating miR-214/Akt/mTOR axis. Onco Targets Ther. 2019;12:8841–8851.
   PubMed Web of Science ®Google Scholar
• Xu C, Zhu LX, Sun DM, et al. Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p. Eur Rev Med Pharmacol Sci. 2020;24(4):1672–1681.
   PubMed Web of Science ®Google Scholar
• Wan YY, Yao ZH, Chen WJ, et al. The lncRNA NORAD/miR-520a-3p facilitates malignancy in non-small cell lung cancer via PI3k/Akt/mTOR signaling pathway. Onco Targets Ther. 2021;13:1533–1544.
   Web of Science ®Google Scholar
• Sun DS, Guan CH, Wang WN, et al. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis. Microvasc Res. 2021;134:104120.
   PubMed Web of Science ®Google Scholar
• Yang X, Cai JB, Peng R, et al. The long noncoding RNA NORAD enhances the TGF-β pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. J Cell Physiol. 2019;234(7):12051–12060.
   PubMed Web of Science ®Google Scholar
• Cao XL, Zhang GP, Li T, et al. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression. Genes Genomics. 2020;42(11):1361–1368.
   PubMed Web of Science ®Google Scholar
• Sur S, Sasaki R, Devhare P, et al. Association between microRNA-373 and long noncoding RNA NORAD in hepatitis C virus-infected hepatocytes impairs wee1 expression for growth promotion. J Virol. 2018;92(20):e01215–e01218.
   PubMed Web of Science ®Google Scholar
• Wang LN, Yuan XY, Lian LF, et al. Knockdown of lncRNA NORAD inhibits the proliferation, inflammation and fibrosis of human mesangial cells under high-glucose conditions by regulating the miR-485/NRF1 axis. Exp Ther Med. 2021;22(2):874.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhu YK, and Liu SJ, et al. NORAD lentivirus shRNA mitigates fibrosis and inflammatory responses in diabetic cardiomyopathy via the ceRNA network of NORAD/miR-125a-3p/Fyn. Inflamm Res. 2021;70(10–12):1113-1127.
   Web of Science ®Google Scholar
• Xiong XJ, Liu JH, He Q, et al. Long non-coding RNA NORAD aggravates acute myocardial infarction by promoting fibrosis and apoptosis via miR −577/COBLL1 axis. Environmental Toxicology. 2021;36(11):2256–2265.
   PubMed Web of Science ®Google Scholar
• Formosa A, Markert EK, Lena AM, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33(44):5173–5182.
   PubMed Web of Science ®Google Scholar
• Yang ZH, Chen WZ, Wang Y, et al. CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR-495-3p to regulate PDL1 expression. Cell Biol Int. 2021;45(7):1423–1435.
   PubMed Web of Science ®Google Scholar
• Li XJ, Song YX, Liu D, et al. MiR-495 promotes senescence of mesenchymal stem cells by targeting Bmi-1. Cell Physiol Biochem. 2017;42(2):780–796.
   PubMedGoogle Scholar
• Hu F, Tong JK, Deng BL, et al. MiR-495 regulates macrophage M1/M2 polarization and insulin resistance in high-fat diet-fed mice via targeting FTO. Pflugers Arch. 2019;471(11–12):1529–1537.
   PubMed Web of Science ®Google Scholar
• Xia DM, Yao RQ, Zhou PY, et al. LncRNA NEAT1 reversed the hindering effects of miR-495-3p/STAT3 axis and miR-211/PI3K/AKT axis on sepsis-relevant inflammation. Mol Immunol. 2020;117:168–179.
   PubMed Web of Science ®Google Scholar
• Zhang RG, Guo CX, Liu T, et al. MicroRNA miR-495 regulates the development of Hepatocellular Carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3). Bioengineered. 2021;12(1):6902–6912.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhuang JH, Wang GD, et al. MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1. Exp Ther Med. 2018;15(1):1150–1158.
   PubMed Web of Science ®Google Scholar
• Yin GZ, Liu ZK, Wang YF, et al. ZNF503 accelerates aggressiveness of hepatocellular carcinoma cells by down-regulation of GATA3 expression and regulated by microRNA-495. Am J Transl Res. 2019;11(6):3426–3437.
   PubMed Web of Science ®Google Scholar
• Guo BY, Hui Q, Xu ZS, et al. miR-495 inhibits the growth of fibroblasts in hypertrophic scars. Aging (Albany NY). 2019;11(9):2898–2910.
   PubMedGoogle Scholar
• Wang XW, In HY, Jiang SF, et al. MicroRNA-495 inhibits the high glucose-induced inflammation, differentiation and extracellular matrix accumulation of cardiac fibroblasts through downregulation of NOD1. Cell Mol Biol Lett. 2018;23(1):23.
   PubMed Web of Science ®Google Scholar
• Hou Y, Li H, Huo W. MicroRNA-495 alleviates ulcerative interstitial cystitis via inactivating the JAK-STAT signaling pathway by inhibiting JAK3. Int Urogynecol J. 2021;32(5):1253–1263.
   PubMed Web of Science ®Google Scholar